A patient reportedly went to the emergency room based on a blood test that Theranos had to retract
Those Edison machines are Theranos' main claim to fame - CEO Elizabeth Holmes rose to prominence on the huge promise that with Edison, Theranos can test for blood-borne diseases with only a pinprick of blood from a fingertip.
But amid larger concerns over the accuracy and viability of the Edison technology, Theranos has told federal regulators that it's thrown out all results from 2014 and 2015.
That includes tests that Theranos did with Edison, as well as the ones it performed with traditional lab equipment, according to the Journal report. That means that anybody who got a Theranos blood test during that period may have gotten wrong results.
The Journal report indicates that physicians in Phoenix have gotten corrected results from Theranos in recent weeks. In fact, one patient went to the emergency room in 2014 based on a Theranos blood test result, says the report - a result that's now been amended.
The move to throw the test results out is a sign that Theranos is showing government agencies that it can regulate its own shortcomings. That's important, because Theranos is facing a criminal investigation, and it's trying to prevent further problems.
Theranos was not immediately available for comment.
- 479 leaked photos purporting to show Putin's secret palace, with an ice rink and pole-dancing room, published by Navalny foundation
- SEBI is hiring young graduate professionals for a monthly stipend of ₹60,000, last date is January 25
- The first pig-heart transplant patient was denied a human heart after failing to follow doctors' orders
- This Indian couple plans to get married in a Hogwarts-themed metaverse to beat the pandemic's restrictions
- Here are some of Netaji’s inspirational quotes as India remembers its valiant fighter
- Lifecycle of cryptocurrencies – From creation to trade and destruction
- Reliance Industries net profit more than triples in the last eight quarters to $2.8 billion
- Reliance Retail earns $1.3 billion more than its best-ever quarter